An EORTC Randomized Phase III Trial of Three Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer (NSCLC)

James Metz, MD
University of Pennsylvania Cancer
Last Modified: May 12, 2001

Presenter: J. P. Van Meerbeeck
Affiliation: EORTC

Background:
  • Combination chemotherapy improves survival in advanced NSCLC based on numerous reports. Cisplatin based chemotherapy has remained the standard regimen used in most studies. This study was designed to compare 3 different chemotherapy regimens, 2 containing cisplatin and one non cisplatin based regimen.
Materials and Methods:
  • 480 patients randomized with 10 patients non- eligle for analysis
  • Patients were randomized between Cisplatin/Paclitaxel (Arm A), Cisplatin/Gemcytabine (Arm B), and Gemcytabine/Paclitaxel (Arm C)
  • Patient characteristics were well balanced between arms
Results:
  • There was no difference in response rates between the control arm (A) and experimental arms (B and C).
  • There was no significant difference in median survival between the arms
  • Arm B had an increased incidence of thrombocytopenia and anemia, but no increased incidence of clinical complications.
  • There was no significant difference in non hematologic toxicity
Authors' Conclusions
  • Both experimental arms failed to show superiority over the control arm
  • There was increased hematologic toxicity with the Gemcytabine/Cisplatin combination without increased clinical complications
  • Quality of life analysis is ongoing
Clinical/Scientific Implications:
  • This trial is disappointing for non cisplatin based chemotherapy supporters
  • Future reference regimens should include cisplatin
  • Questions remain if higher doses of paclitaxel will show a benefit than those used in this study

ASCO Abstract 1228

Saturday | Sunday | Monday | Tuesday

OncoLink ASCO 2001 coverage is provided by an unrestricted educational grant from Amgen


A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
R
S
T
U
V
X
Y
Z
#
 
A
B
C
E
F
G
H
K
L
M
N
O
P
R
S
T
U
V
 
 
Stay informed with the latest information from OncoLink!   Subscribe to OncoLink eNews
View our newsletter archives